Navigation Links
Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
Date:8/3/2009

NEW YORK, Aug. 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it has reached agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design of a Phase 3 trial for its PI3K/Akt pathway inhibitor, KRX-0401 (perifosine), in relapsed or relapsed / refractory multiple myeloma patients previously treated with bortezomib (VELCADE((R))). The SPA provides agreement that the Phase 3 study design adequately addresses objectives in support of a regulatory submission. The trial, entitled, "A Phase 3 Randomized Study to Assess the Efficacy and Safety of Perifosine Added to the Combination of Bortezomib and Dexamethasone in Multiple Myeloma Patients Previously Treated with Bortezomib" will be a double-blind, placebo-controlled trial comparing the efficacy and safety of KRX-0401 vs. placebo when combined with bortezomib and dexamethasone. The trial, powered at 90%, will enroll approximately 400 patients with relapsed or relapsed / refractory multiple myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety.

Dr. Kenneth Anderson, Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute, commented, "Perifosine holds great promise for multiple myeloma patients worldwide. We at Dana-Farber, along with our other collaborating multiple myeloma centers, are encouraged to see perifosine move into this final stage of testing, and look forward to working with Keryx on this exciting trial."

Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute and Study Chairman for the KRX-0401 Phase 3 trial, added, "Perifosine has shown considerable activity when combined with bortez
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
2. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
3. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
4. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
5. Keryx Biopharmaceuticals Receives Nasdaq Notification
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
7. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
8. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
10. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) to be Presented at the Upcoming American Society of Hematology Meeting in Atlanta, Georgia
11. Presentation Time Correction: Keryx Biopharmaceuticals Presents at 12:00pm, ET Tomorrow (Oct. 3) at William Blair & Company Small-Cap Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... moving too,slowly in reducing maternal deaths, enabling young people ... experts, advocates and,activists agreed today., Existing commitments and ... other reproductive health challenges, according to An Open,Letter to ... here., Some 1,300 people from civil society and ...
... 31, 2007 Today researchers report a newly ... of prostate cancer in African American men. This ... associated with prostate cancer in high-risk populations, is published ... , Prostate cancer is the second leading cause of ...
... have same benefit for Caucasians , , WEDNESDAY, Oct. 31 ... experimental chemotherapy drug after surgery improved survival rates for ... of the trial won,t mean much for Americans with ... as "investigational" in the United States. But the study ...
... 31 An influential report on,cancer prevention provides ... policy, say doctors with the Physicians Committee for,Responsible ... the American,Institute for Cancer Research (AICR). A comprehensive ... previous research showing that meat and,alcohol consumption increase ...
... 31 /PRNewswire-FirstCall/ - Haemacure Corporation,(TSX:HAE), a specialty bio-therapeutics ... Acumen BioFin Rodman & Renshaw 9th Annual,Healthcare Conference, ... the New York,Palace Hotel in New York. ... of the presentation and,post the associated slides via ...
... Silicon Valley Marathon and Expo, Who: Lifespring Health ( http://www.lifespringhealth.com ) offers ... to help people afford a healthy lifestyle ... Silicon Valley Marathon. The run is set in San Jose and is a ... Expo -- Saturday 11/3 from 10 am - 4 pm ...
Cached Medicine News:Health News:Diverse Partners Renew Commitment to Reproductive Health, Rights in Asia 2Health News:Diverse Partners Renew Commitment to Reproductive Health, Rights in Asia 3Health News:Scientists discover genetic variant associated with prostate cancer in African Americans 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Just-Released Cancer Report Provides New Ammunition for Farm Bill Reform Effort 2Health News:Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec 2
(Date:12/24/2014)... Dec. 24, 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. ... company that specializes in the patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) released unaudited preliminary financial results ... Fiscal Year 2015 Ended September 30, ... million compared with $14.7 million in 1Q14 with ...
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
(Date:12/24/2014)... CRANBURY, N.J. and FARMINGTON, ... Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical ... treatment of diseases with significant unmet medical need ... closed on a private placement of 2,050,000 shares ... to purchase 24,949,325 shares of its common stock.  ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... (PDL) (NASDAQ: PDLI ) today announced revenue guidance ... $72 million, as compared with actual results of $76 million ... Total anticipated revenue for the year ended December 31, 2011 ... million for the year ended December 31, 2010, a five ...
... & Leviton LLP is investigating whether the Board of ... (NASDAQ: ISTA ) breached their fiduciary duties ... ("Valeant") (NASDAQ: VRX ) to acquire the ... The investigation centers on whether ISTA,s ...
Cached Medicine Technology:PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million 2PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million 3PDL BioPharma Provides Fourth Quarter 2011 Revenue Guidance of $72 Million 4
Traditional design utility pliers have adjustable jaws. Good all purpose plier for handling Steinmann Pins, K-Wires, screws and rods. 10mm jaw tip....
The Wire Cutters are designed to cut Kirschner wires up to 2.5 mm diameter easily and smoothly. They are particularly useful for external fixation applications. The Wire Cutters shear fixation wires ...
Curved osteotome for bone removing....
... Spectral system is a combination Spectral Optical ... (SLO) system that provides suberb, high-quality images ... With the advancements of spectral technology, OTI's ... to 27,000 A-Scans per second and provide ...
Medicine Products: